

Roche announces availability of FoundationOne Liquid

Sept. 27, 2018—[Roche](#) announced that its FoundationOne Liquid, a blood-based genomic profiling test, is available worldwide. FoundationOne Liquid can identify circulating tumor DNA in the blood of people with cancer and can identify 70 of the most commonly mutated genes in solid tumors, including microsatellite instability.

“FoundationOne Liquid meets a compelling need for comprehensive genomic profiling for people who have insufficient or inadequate tissue, including those with advanced non-small cell lung cancer, where an estimated 15 percent of patients are not eligible for tissue biopsy and approximately 10 percent have a biopsy size that is insufficient to evaluate,” according to a press release from Roche. The blood sample is sent to a Foundation Medicine lab, where the test is performed using next-generation sequencing to analyze the four main classes of genomic alterations as well as microsatellite instability, an indicator that may help inform immunotherapy treatment decisions using ctDNA isolated from plasma derived from peripheral whole blood.

FoundationOne Liquid complements FoundationOne CDx, a tissue-based genomic profiling test launched in the U.S. in March.